tiprankstipranks
Trending News
More News >
Lantern Pharma, Inc. (LTRN)
NASDAQ:LTRN
US Market
Advertisement

Lantern Pharma (LTRN) AI Stock Analysis

Compare
285 Followers

Top Page

LTRN

Lantern Pharma

(NASDAQ:LTRN)

Rating:45Neutral
Price Target:
Lantern Pharma is innovating with AI in oncology, achieving key clinical and regulatory milestones. However, the financial outlook is challenging due to zero revenue and cash flow concerns, necessitating additional funding. Technicals are stable but show potential volatility.

Lantern Pharma (LTRN) vs. SPDR S&P 500 ETF (SPY)

Lantern Pharma Business Overview & Revenue Model

Company DescriptionLantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
How the Company Makes MoneyLantern Pharma generates revenue primarily through the development and commercialization of its drug candidates. The company uses its proprietary RADR platform to identify biomarkers and genetic signatures that can predict patient response to its drug candidates, thereby reducing time and cost associated with drug development. Revenue streams include out-licensing partnerships, collaborations with pharmaceutical companies, and potentially, future sales of approved drugs. These partnerships often involve milestone payments, royalties, and shared development costs, which are significant contributors to the company's earnings. As Lantern Pharma advances its drug pipeline and secures additional partnerships, these factors are expected to drive financial growth.

Lantern Pharma Earnings Call Summary

Earnings Call Date:Aug 13, 2025
(Q1-2025)
|
% Change Since: |
Next Earnings Date:Nov 05, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant advancements in clinical trials and AI platform development, demonstrating both financial discipline and strategic expansion. However, challenges remain in securing additional funding and successfully commercializing AI data modules.
Q1-2025 Updates
Positive Updates
Clinical Pipeline Advancements
The Phase 1a trial for LP-184 is progressing well, with enrollment expected to be complete by June 2025. Dual fast track designations for LP-184 in glioblastoma and triple-negative breast cancer have been granted, opening paths toward regulatory approvals.
AI Platform Expansion
The radar AI platform has expanded to over 200 billion oncology-focused data points. Plans are in place to open the platform to the scientific community, potentially creating new revenue streams.
Financial Discipline and Efficiency
Quarterly net loss decreased to $4.5 million from $5.4 million the previous year, demonstrating operational efficiency. Cash and marketable securities stand at $19.7 million, providing runway until at least mid-May 2026.
HARMONIC Phase 2 Trial Progress
Strong progress in the HARMONIC trial for LP-300, with positive preliminary data showing an 86% clinical benefit rate. Expansion in Asian markets is underway.
Negative Updates
Need for Additional Funding
Despite maintaining financial discipline, there is a need for additional funding in the near future to continue operations and development.
Challenges in Data Commercialization
Opening AI modules to the market faces challenges in scalability, data quality, and establishing a sustainable business model.
Company Guidance
In the first quarter of 2025, Lantern Pharma made significant progress in its clinical pipeline and AI platform advancements, setting the stage for multiple catalysts in the coming quarters. The company advanced its Phase 1a trial for LP-184, with enrollment nearing completion at 62 to 65 patients, and began observing early indications of clinical activity. Lantern's proprietary radar AI platform expanded to over 200 billion oncology-focused data points, and the company announced plans to commercialize its AI modules, starting with a blood-brain barrier prediction tool. Financially, Lantern reduced its net loss to approximately $4.5 million, down from $5.4 million the previous year, while maintaining a cash position of $19.7 million. The company also highlighted strategic initiatives for maximizing shareholder value, including potential partnerships and commercialization of AI capabilities.

Lantern Pharma Financial Statement Overview

Summary
Lantern Pharma faces significant financial challenges, with zero revenue and increasing operational losses. Despite a strong balance sheet with low debt, the negative cash flow situation raises concerns about long-term viability and the need for additional financing.
Income Statement
20
Very Negative
Lantern Pharma has consistently reported zero revenue, indicating a pre-revenue stage or significant challenges in generating sales. The company's net losses have increased substantially over the years, reflecting mounting operational challenges. The EBIT and EBITDA margins are negative due to high operational expenses without corresponding revenue, undermining profitability prospects.
Balance Sheet
60
Neutral
The company maintains a strong equity position relative to its assets, with a high equity ratio, reflecting financial stability. The debt-to-equity ratio is low, indicating minimal reliance on debt financing, which reduces financial risk. However, the consistent increase in liabilities and decreasing cash reserves could affect future liquidity and operational capacity.
Cash Flow
30
Negative
Lantern Pharma exhibits negative operating and free cash flows, indicating cash burn without revenue inflow. Despite substantial financing inflows in prior years, the inability to generate positive cash flows from operations is concerning. The lack of free cash flow growth highlights potential sustainability challenges.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue100.65K0.000.000.000.000.00
Gross Profit-6.61K-190.49K-174.84K-154.68K-97.42K-3.39K
EBITDA-20.49M-20.59M-15.79M-14.42M-12.27M-5.90M
Net Income-19.25M-20.78M-15.96M-14.26M-12.36M-5.91M
Balance Sheet
Total Assets17.42M25.57M43.65M58.84M73.95M20.36M
Cash, Cash Equivalents and Short-Term Investments15.90M24.01M41.30M55.20M70.73M19.23M
Total Debt145.04K243.66K234.47K52.89K204.95K108.50K
Total Liabilities4.90M4.38M2.74M2.80M2.38M660.84K
Stockholders Equity12.52M21.19M40.91M56.04M71.57M19.70M
Cash Flow
Free Cash Flow-17.87M-17.83M-14.37M-12.80M-10.61M-5.67M
Operating Cash Flow-17.87M-17.81M-14.35M-12.77M-10.59M-5.65M
Investing Cash Flow10.96M3.37M-930.21K179.27K-19.53M-16.14K
Financing Cash Flow11.99K66.71K-500.00K-2.18M63.42M23.66M

Lantern Pharma Technical Analysis

Technical Analysis Sentiment
Positive
Last Price4.31
Price Trends
50DMA
4.13
Positive
100DMA
3.79
Positive
200DMA
3.80
Positive
Market Momentum
MACD
-0.02
Positive
RSI
50.42
Neutral
STOCH
42.68
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LTRN, the sentiment is Positive. The current price of 4.31 is below the 20-day moving average (MA) of 4.39, above the 50-day MA of 4.13, and above the 200-day MA of 3.80, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 50.42 is Neutral, neither overbought nor oversold. The STOCH value of 42.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LTRN.

Lantern Pharma Risk Analysis

Lantern Pharma disclosed 72 risk factors in its most recent earnings report. Lantern Pharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Lantern Pharma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.92B-0.43-41.67%2.21%22.29%-1.85%
48
Neutral
$61.73M-100.55%-100.00%-22.09%
45
Neutral
$45.36M-88.59%-8.47%
39
Underperform
$66.99M-150.82%
38
Underperform
$84.62M0.00%
36
Underperform
$136.26M-73.46%62.69%
34
Underperform
$34.43M-44.71%44.85%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
LTRN
Lantern Pharma
4.31
0.89
26.02%
FBRX
Forte Biosciences
11.26
3.65
47.96%
APLT
Applied Therapeutics
0.47
-5.23
-91.75%
HOWL
Werewolf Therapeutics
1.35
-0.67
-33.17%
ANTX
AN2 Therapeutics, Inc.
1.26
0.24
23.53%
OKYO
OKYO Pharma Limited Sponsored ADR
2.26
1.24
121.57%

Lantern Pharma Corporate Events

Business Operations and StrategyFinancial Disclosures
Lantern Pharma Reports Q4 2024 Financial Results and AI Progress
Positive
Mar 27, 2025

On March 27, 2025, Lantern Pharma announced its financial results for the fourth quarter and full year ended December 31, 2024, alongside updates on its AI-driven drug candidates and operational progress. The company reported significant advancements in its clinical programs, including the HARMONIC™ trial for LP-300, which showed promising results in never-smoker NSCLC patients, and the continued progress of LP-184 and LP-284 in clinical trials. Lantern Pharma also highlighted its innovative AI capabilities, such as the RADR® platform surpassing 100 billion oncology-specific data points and the development of an AI-powered ADC module, which could significantly reduce development timelines and costs.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 02, 2025